227. Osler disease
49 clinical trials,   69 drugs   (DrugBank: 21 drugs),   23 drug target genes,   132 drug target pathways

Searched query = "Osler disease", "Hereditary hemorrhagic telangiectasia", "Osler-Weber-Rendu disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01408030
(ClinicalTrials.gov)
August 20111/8/2011North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)North American Study of Epistaxis in HHT (NOSE)Telangiectasia, Hereditary Hemorrhagic;EpistaxisDrug: Sterile saline;Drug: Bevacizumab;Drug: Estriol;Drug: Tranexamic AcidJames GossageHHT Foundation InternationalCompleted18 YearsN/AAll123Phase 2United States
2NCT01031992
(ClinicalTrials.gov)
March 200211/12/2009Tranexamic Acid and Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)Efficacy of Tranexamic Acid Taken Orally in Patients With Hereditary Hemorrhagic TelangiectasiaHereditary Hemorrhagic TelangiectasiaDrug: Tranexamic acid first, than placebo;Drug: First placebo, than Tranexamic acid.University Hospital, SaarlandPharmacia GmbH, Erlangen, Germany;Baxter Healthcare CorporationCompleted18 YearsN/ABoth23Phase 3Germany